SVRA Aug 2024 2.500 put
| Previous Close | 0.9500 |
| Open | 0.8000 |
| Bid | 0.3500 |
| Ask | 0.8000 |
| Strike | 2.50 |
| Expire Date | 2024-08-16 |
| Day's Range | 0.8000 - 1.0500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 150 |
Business WireSavara to Present at the Jefferies Global Healthcare Conference
LANGHORNE, Pa., May 29, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am PT/10:00am ET. A live webcast of the fireside chat will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
Business WireSavara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
LANGHORNE, Pa., May 19, 2024--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA. Savara’s partner, Trillium Health LLC, presented a poster on the laboratory blood test that was recently developed to aid in the diagnosis of aPAP.
Business WireSavara Announces New Employment Inducement Grant
AUSTIN, Texas, May 16, 2024--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
